The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Awesome!! Good find Gix.
Sirco Heart 3 in one yoghurt seems to be coming along. The website is being updated to show it is FF + Plant Stanols + Immunity Friends Nutrients.
https://www.sircoheart.com
I think this is caused by my bad luck. I was going to buy some more shares this morning at .50, but waited until after a meeting, by which time they had gone up 10%, so didn't bother.
You can thank my bad luck.
7 - 9 February, 2024 Milan
DSM are diamond geezers, Atalantia are Gold
https://probiotaevent.com/live/en/page/sponsors
They've just taken the old website and replaced the image I think. Now FF seems to lower cholesterol. They don't mention any other ingredients. The product design looks nice.
Moonshot goal:
the term moonshot entered the dictionary, defined as a difficult or expensive task, the outcome of which is expected to have great significance.
The transformation will be implemented on three specific moon goals: first, national invention patents for raw materials and formulas, second, research and development of new functions and heavy-functional large single products, and third, forward-looking basic research such as anti-aging and precision nutrition.
Its second moon goal is also being carried out in an orderly manner. Thomson Beijian, together with a number of authoritative institutions, announced the results of light hormone experiments aimed at improving blood flow health in Chinese people, and developed related products that are conducive to cardiovascular health with "Fruitflow®" as the main direction.
A total of 134 products were successfully registered in the first 6 months of 2022. Of which, 80 products had filed for registration last year, whilst the remaining 54 had filed for registration this year (2022).
https://www.foodnavigator-asia.com/Article/2022/07/20/most-blue-hat-health-foods-approved-this-year-made-immune-antioxidant-claims
It’s a bit vague, but gives a bit of an idea on the timeframe for product blue hat registration.
But DSM are still taking a large chunk of change. Step down 2 starts Jan 01st, which should improve our situation.
Would be good to know how many products are with SAMR for approval. We know BH have a couple ready to launch and we know that FF+O3 agreement was complimentary to the BH agreement. I can only imagine that FF+O3 is part of the approvals too. So at least 3 products will be launch ready when approved. I'm sure that more than 3 will be with SAMR for approval. The BH strategy is to create a number of product formulas, keeping the best formulas for themselves and offering others to customers.
I would assume the evaluation methods have been reviewed and approved by SAMR before the work commenced, or perhaps alongside the study work. It was likely this that results in the test scope changing, which resulted in a changing number of studies. Then SAMR reps are involved in the testing and submission. So I think approval is pretty much a box ticking exercise.
We are coming up to 3 months since submission. It is a dual track submission, FF + Products. We know that Product approval use to take years, but these days it has been reduced to 6 months from submission. So if FF can be done within that timescale, then the product approvals will be the critical path and land us in 2024 Q1. It's all guesswork.
I’d forget about them and check them again in 2 years.
It’s slowly collapsing like a flan in a cupboard.
I would think at least 6 months, so Feb / March at the earliest. They will only order when it is approved and it will take time to get the goods ready for a launch.
What about existing DSM customers/prospective customers? I think the RNS' imply that the existing DSM setup for platelet aggregation is expected to bring significant multiples of current total FF sales.
Byhealth Co., Ltd reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 7,782.28 million compared to CNY 6,159.88 million a year ago. Revenue was CNY 7,782.28 million compared to CNY 6,159.88 million a year ago.
And on the DSM side of things, the prospective sales pipeline remains at substantial multiples of current income. To me that means there are 1 or 2 major players planning to launch based on platelet aggregation claim. Then we have interest from ‘truly global’ for gut modulation. Can’t imagine anything happening on that for a while due to patent and general slowness.